Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Acetaminophen plus Diphenhydramine vs placebo Death ‐ not reported · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions Pharmacological interventions for the prevention of allergic and febrile non‐haemolytic transfusion reactions (2010) · Cochrane | RR 0 [0, 0] | 0 studies · 0 participants | Ungraded |
Acetaminophen plus Diphenhydramine vs placebo Adverse events · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions Pharmacological interventions for the prevention of allergic and febrile non‐haemolytic transfusion reactions (2010) · Cochrane | RR 0 [0, 0] | 0 studies · 0 participants | Ungraded |
Acetaminophen plus Diphenhydramine vs placebo Allergic reactions (urticaria with or without pruritus) ‐ Intention‐to treat analysis · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions Pharmacological interventions for the prevention of allergic and febrile non‐haemolytic transfusion reactions (2010) · Cochrane | RR 1.45 [0.78, 2.72] | 1 study · 334 participants | Very low |
Acetaminophen plus Diphenhydrammine vs placebo (Unit of randomisation: transfusion) Fever ‐ Per protocol analysis · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions Pharmacological interventions for the prevention of allergic and febrile non‐haemolytic transfusion reactions (2010) · Cochrane | RR 1.77 [0.57, 5.49] | 1 study · 98 participants | Low |
Acetaminophen plus Diphenhydrammine vs placebo (Unit of randomisation: transfusion) Anaphylatic reactions ‐ not reported · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions Pharmacological interventions for the prevention of allergic and febrile non‐haemolytic transfusion reactions (2010) · Cochrane | RR 0 [0, 0] | 0 studies · 0 participants | Ungraded |
Acetaminophen plus Diphenhydrammine vs placebo (Unit of randomisation: transfusion) Hives ‐ Per protocol analysis · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions Pharmacological interventions for the prevention of allergic and febrile non‐haemolytic transfusion reactions (2010) · Cochrane | RR 0.13 [0.01, 2.39] | 1 study · 98 participants | Low |
Acetaminophen plus Diphenhydrammine vs placebo (Unit of randomisation: transfusion) Death ‐ not reported · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions Pharmacological interventions for the prevention of allergic and febrile non‐haemolytic transfusion reactions (2010) · Cochrane | RR 0 [0, 0] | 0 studies · 0 participants | Ungraded |
HES vs other fluids Renal Replacement Therapy ‐ Sepsis · patients with Intravascular Volume Depletion Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function (2010) · Cochrane | RR 1.59 [1.2, 2.1] | 3 studies · 702 participants | High |
HES vs other fluids RIFLE (Failure) ‐ Non‐Sepsis · patients with Intravascular Volume Depletion Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function (2010) · Cochrane | RR 0.49 [0.07, 3.73] | 2 studies · 185 participants | Moderate |
High MW HES vs Low MW HES RIFLE (Risk or worse) · patients with Intravascular Volume Depletion Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function (2010) · Cochrane | RR 0.54 [0.05, 5.59] | 2 studies · 113 participants | Moderate |
High MW HES vs Low MW HES RIFLE (Injury or worse) · patients with Intravascular Volume Depletion Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function (2010) · Cochrane | RR 3.21 [0.14, 75.68] | 3 studies · 162 participants | Moderate |
High MW HES vs Low MW HES RIFLE (Failure) · patients with Intravascular Volume Depletion Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function (2010) · Cochrane | no estimate extracted | 3 studies · 162 participants | Moderate |
HES vs other fluids Renal Replacement Therapy ‐ Non‐Sepsis · patients with Intravascular Volume Depletion Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function (2010) · Cochrane | RR 0.44 [0.14, 1.38] | 8 studies · 487 participants | Moderate |
HES vs other fluids Renal Failure (author defined) ‐ Sepsis · patients with Intravascular Volume Depletion Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function (2010) · Cochrane | RR 1.55 [1.22, 1.96] | 4 studies · 832 participants | Moderate |
HES vs other fluids Renal Failure (author defined) ‐ Non‐Sepsis · patients with Intravascular Volume Depletion Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function (2010) · Cochrane | RR 1.13 [0.57, 2.25] | 5 studies · 367 participants | Low |
HES vs other fluids RIFLE (Risk or worse) ‐ Sepsis · patients with Intravascular Volume Depletion Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function (2010) · Cochrane | RR 1.28 [0.81, 2.02] | 2 studies · 140 participants | High |
HES vs other fluids RIFLE (Risk or worse) ‐ Non‐Sepsis · patients with Intravascular Volume Depletion Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function (2010) · Cochrane | RR 0.88 [0.27, 2.85] | 2 studies · 185 participants | Moderate |
HES vs other fluids RIFLE (Injury or worse) ‐ Sepsis · patients with Intravascular Volume Depletion Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function (2010) · Cochrane | RR 1.39 [0.84, 2.3] | 2 studies · 140 participants | High |
HES vs other fluids RIFLE (Injury or worse) ‐ Non‐Sepsis · patients with Intravascular Volume Depletion Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function (2010) · Cochrane | RR 0.81 [0.12, 5.4] | 2 studies · 185 participants | Moderate |
HES vs other fluids RIFLE (Failure) ‐ Sepsis · patients with Intravascular Volume Depletion Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function (2010) · Cochrane | RR 1.45 [0.8, 2.64] | 2 studies · 140 participants | High |
bed rest vs advice to stay active Pain intensity, short‐term · patients with acute low‐back pain Advice to rest in bed versus advice to stay active for acute low‐back pain and sciatica (2010) · Cochrane | no estimate extracted | 3 studies · 480 participants | Low |
bed rest vs advice to stay active Pain intensity, long‐term · patients with acute low‐back pain Advice to rest in bed versus advice to stay active for acute low‐back pain and sciatica (2010) · Cochrane | no estimate extracted | 2 studies · 393 participants | Moderate |
bed rest vs advice to stay active Functional status, short‐term · patients with acute low‐back pain Advice to rest in bed versus advice to stay active for acute low‐back pain and sciatica (2010) · Cochrane | no estimate extracted | 2 studies · 400 participants | Moderate |
bed rest vs advice to stay active Functional status, long‐term · patients with acute low‐back pain Advice to rest in bed versus advice to stay active for acute low‐back pain and sciatica (2010) · Cochrane | no estimate extracted | 2 studies · 393 participants | Moderate |
bed rest vs advice to stay active Pain intensity, short‐term · patients with sciatica Advice to rest in bed versus advice to stay active for acute low‐back pain and sciatica (2010) · Cochrane | no estimate extracted | 2 studies · 346 participants | Moderate |
bed rest vs advice to stay active Pain intensity, long‐term · patients with sciatica Advice to rest in bed versus advice to stay active for acute low‐back pain and sciatica (2010) · Cochrane | no estimate extracted | 2 studies · 330 participants | Moderate |
bed rest vs advice to stay active Functional status, short‐term · patients with sciatica Advice to rest in bed versus advice to stay active for acute low‐back pain and sciatica (2010) · Cochrane | no estimate extracted | 2 studies · 346 participants | Moderate |
bed rest vs advice to stay active Functional status, long‐term · patients with sciatica Advice to rest in bed versus advice to stay active for acute low‐back pain and sciatica (2010) · Cochrane | no estimate extracted | 2 studies · 330 participants | Moderate |
Intervention NR ACR‐50 · patients with rheumatoid arthritis Balance training (proprioceptive training) for patients with rheumatoid arthritis (2010) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR Pain · patients with rheumatoid arthritis Balance training (proprioceptive training) for patients with rheumatoid arthritis (2010) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR DAS (low or remission) · patients with rheumatoid arthritis Balance training (proprioceptive training) for patients with rheumatoid arthritis (2010) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR HAQ for function · patients with rheumatoid arthritis Balance training (proprioceptive training) for patients with rheumatoid arthritis (2010) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR Gait · patients with rheumatoid arthritis Balance training (proprioceptive training) for patients with rheumatoid arthritis (2010) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR Adverse effects · patients with rheumatoid arthritis Balance training (proprioceptive training) for patients with rheumatoid arthritis (2010) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR Discontinuation rates · patients with rheumatoid arthritis Balance training (proprioceptive training) for patients with rheumatoid arthritis (2010) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Levomepromazine vs Typical antipsychotics Leaving the study early ‐ short term ‐ any reason · patients with schizophrenia Levomepromazine for schizophrenia (2010) · Cochrane | RR 1.11 [0.45, 2.74] | 1 study · 41 participants | Low |
Levomepromazine vs Atypical antipsychotics Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia Levomepromazine for schizophrenia (2010) · Cochrane | RR 0.83 [0.4, 1.74] | 2 studies · 106 participants | Very low |
Levomepromazine vs Atypical antipsychotics Leaving the study early ‐ short term ‐ due to patient deterioration · patients with schizophrenia Levomepromazine for schizophrenia (2010) · Cochrane | RR 5 [0.25, 98.27] | 1 study · 42 participants | Moderate |
Levomepromazine vs Atypical antipsychotics Leaving the study early ‐ short term ‐ lost to · patients with schizophrenia Levomepromazine for schizophrenia (2010) · Cochrane | RR 0.33 [0.01, 7.74] | 1 study · 42 participants | Low |
Levomepromazine vs Typical antipsychotics Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia Levomepromazine for schizophrenia (2010) · Cochrane | RR 0.95 [0.22, 4.18] | 1 study · 41 participants | Low |
Levomepromazine vs Typical antipsychotics Leaving the study early ‐ short term ‐ due to adverse events · patients with schizophrenia Levomepromazine for schizophrenia (2010) · Cochrane | RR 4.77 [0.24, 93.67] | 1 study · 41 participants | Low |
Levomepromazine vs Typical antipsychotics Leaving the study early ‐ medium term ‐ any reason · patients with schizophrenia Levomepromazine for schizophrenia (2010) · Cochrane | RR 2 [0.2, 19.62] | 1 study · 28 participants | Very low |
Levomepromazine vs Typical antipsychotics Leaving the study early ‐ long term ‐ any reason · patients with schizophrenia Levomepromazine for schizophrenia (2010) · Cochrane | RR 0.4 [0.09, 1.81] | 1 study · 38 participants | Moderate |
Levomepromazine vs Typical antipsychotics Leaving the study early ‐ long term ‐ due to adverse events · patients with schizophrenia Levomepromazine for schizophrenia (2010) · Cochrane | RR 1 [0.07, 14.85] | 1 study · 38 participants | Moderate |
Levomepromazine vs Typical antipsychotics Leaving the study early ‐ long term ‐ lost to · patients with schizophrenia Levomepromazine for schizophrenia (2010) · Cochrane | RR 1 [0.07, 14.85] | 1 study · 38 participants | Moderate |
Levomepromazine vs Atypical antipsychotics Leaving the study early ‐ short term ‐ any reason · patients with schizophrenia Levomepromazine for schizophrenia (2010) · Cochrane | RR 1 [0.67, 1.49] | 2 studies · 106 participants | Low |
Levomepromazine vs Atypical antipsychotics Leaving the study early ‐ short term ‐ due to adverse events · patients with schizophrenia Levomepromazine for schizophrenia (2010) · Cochrane | RR 5 [0.25, 98.27] | 1 study · 42 participants | Moderate |
Intervention NR Pain level Verbal pain scale. Scale from: 0 to 10. ( · patients with big toe joint osteoarthritis Interventions for treating osteoarthritis of the big toe joint (2010) · Cochrane | no estimate extracted | 1 study · 20 participants | Low |
Intervention NR Physical Function ‐ not measured · patients with big toe joint osteoarthritis Interventions for treating osteoarthritis of the big toe joint (2010) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse effects ( · patients with big toe joint osteoarthritis Interventions for treating osteoarthritis of the big toe joint (2010) · Cochrane | no estimate extracted | NR | No studies |